Breast cancer is a major public health problem all over the world, and the current treatment strategies are not potent enough for some patients, especially those with triple-negative breast cancer. Therefore, novel and more effective treatments are critically needed. Of the current methods, targeted therapy, which not only retains cancer-specific expression but also limits toxicity, is a new strategy for treating cancers. In this study, we have found that the human telomerase reverse transcriptase (hTERT; T) promoter also possesses high target specificity in breast cancer. Moreover, we developed a versatile T-based breast cancer-specific promoter VISA (VP16-Gal4-WPRE integrated systemic amplifier) composite (T-VISA) to target transgene expression in breast tumors, which has stronger activity comparable or higher than that of the cytomegalovirus (CMV) promoter in cancer cells. Thereafter, targeted expression of BikDD (a mutant form of proapoptotic gene Bik) through the T-VISA platform in breast cancer initiated robust antitumor effects and prolonged survival in multiple xenograft and syngeneic orthotopic mouse models of breast tumors with virtually no toxicity in intact mice. Thus, these findings demostrate our T-VISA-BikDD nanoparticles effectively and safely eradicate breast cancer in vitro and in vivo, and are worthy of development in clinical trials treating breast cancer.
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Introduction
As the most common malignancy among women worldwide, breast cancer has the highest mortality rate of all cancers, especially in economically developing countries, with an estimate of 458,400 deaths and 1,383,500 new cases in the world in 2008 (1).
Many effective therapy approaches for treating breast cancer are increasingly possible with state of the art diagnostics and treatments (2) (3) (4) . However, many challenges still exist in choosing the optimal therapeutic strategy for a specific patient population, such as triple-negative and advanced-staged patients who do not respond to current cancer treatment modalities or those who recurred. Therefore, more effective and alternative therapeutic strategies to the treatment of breast cancer are urgently needed.
More recently, there is evidence that shows in addition to current chemotherapy and radiotherapy, targeted therapy can also effectively and preferentially treat cancers (5-7). A delivery vector, which can selectively deliver therapeutic genes to target cells efficiently and safely, is critical for successful targeted cancer therapy (8, 9) . The development of current viral vectors for targeted treatment is restricted by a number of issues such as immunogenicity, toxicity (10, 11) , and potential recombination or complementation (12) . Luckily, nonviral promoter-based targeted therapy has gained widespread attention for its cancer specificity, optimal antitumor activitvies, and less toxicity to surrounding normal cells (13) (14) (15) (16) . Thus, a promoter that is highly active and specific for breast tumor would be ideal for designing such targeted therapy.
By searching the literature and the Serial Analysis of Gene Expression database, we identified several candidate promoters including the human telomerase reverse transcriptase (hTERT; T) (17, 18) , survivin (19, 20) , claudin-4 (21-23), fatty acid synthase (FASN) (24, 25) and β-catenin (26) . After comparing the activities of these promoters in different breast cancer cell lines, we found that the T promoter has the highest potential to be used for targeted breast cancer therapy among all other promoters tested. However, the expression levels of most of the identified promoters are much weaker than the CMV promoter, which holds strong activity without tumor specificity. Fortunately, to resolve this issue, we developed a versatile T-based breast cancer-specific promoter VISA (VP16-Gal4-WPRE integrated systemic amplifier) (13, 14) composite (T-VISA) to target transgene expression in breast tumors, the activity of which is stronger than or comparable to that of CMV in cancer cells.
In order to develop a breast cancer nonviral target therapy approach, we incorporated the BikDD (27, 28) (a mutant form of proapoptotic gene Bik from the Bcl-2 family and possesses potent tumor-killing activity) gene into the T-VISA vector, and detected the cell-killing effects in vitro as well as tumor inhibition characteristics in vivo. In this study, systemic delivery of T-VISA-BikDD nanoparticles (29) preferably targeted the breast cancer cells and significantly suppressed the tumor growth as well as prolonged survival in multiple breast tumor xenograft and syngeneic orthotopic mouse models. Moreover, T-VISA-BikDD demonstrated virtually no toxicity in intact mice, suggesting that the VISA-nanoparticles are worthy of moving into clinical trials.
Materials and Methods
Cell lines and culture. The following cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA) and were passaged in our laboratory for less than six months after resuscitation of frozen aliquots: human breast cancer cell lines (MDA-MB-231, MDA-MB-361, MDA-MB-435, MDA-MB-453,   MDA-MB-468, MCF-7, T47D, BT474, 4T1, Preparation of plasmids and liposome. Plasmids pGL3-T-Luc, pGL3-Survivin-Luc, pGL3-Clandin-4-Luc, pGL3-FASN-Luc, pGL3-β-cateinin-Luc, and pGL3-CMV-Luc containing the T, Survivin, Claudin-4, FASN, β-catenin, and CMV promoter, respectively, to drive the expression of the firefly luciferase gene were previously described (14, 15, 19, 21, 26) . The VISA amplification system was incorporated into the pGL3-T-Luc plasmid to create pGL3-T-VISA-Luc.
To construct the therapeutic plasmids, we replaced the luciferase gene with BikDD, which was digested with BglII/NheI, followed by ligation to the vector backbone. In order to avoid ampicillin resistance in the clinic, the pUK21-T-VISA-BikDD containing kanamycin resistance gene was created by inserting the functional part of pGL3-T-VISA-BikDD vector into Notl and SalI sites of the pUK21 vector. Forty-eight hours later, cells were subjected to lysis and assayed for luciferase activity using the dual-luciferase reporter assay system (Promega) according to the manufacturer's protocol.
To evaluate the tissue distribution of luciferase expression, tissue specimens from tumors and major organs, including the lung, heart, liver, spleen, kidney, and GI (gastrointestinal), were harvested and homogenized (13) . Luciferase assays were performed 48 h post-transfection using a luminometer (Lumat LB9507; Berthold Technologies, Bad Wildbad, Germany), and the protein concentration was determined as previously described (13) . 
Statistical analysis.
The results are given as mean ± SD. Student's t-test was used to compare the differential expression or cytotoxicity effect in cancer and normal groups.
All statistical tests were two-sided. Survival curves were obtained by the Kaplan-Meier method. The difference in survival time between two groups was analysed with the log-rank test. The significance level was set at P < 0.05.
Results

The T promoter is active specifically in breast cancer cells
To explore a breast cancer-specific promoter, we searched for the literature and the Serial Analysis of Gene Expression database and found five candidates: T, Survivin, Claudin-4, FASN and β-catenin (Fig. 1A) . By detecting the activities of these promoters in different breast cancer cell lines and normal cell lines, the T promoter was shown to be highly specific in breast cancer cells with less activity in normal cell lines (Fig. 1B) . These results indicate that the T promoter would be feasible as a targeted therapy for breast cancer.
T-VISA is highly and specifically expressed in breast cancer cells
As described above, the expression level of T promoter in breast tumor was much weaker than the CMV promoter. Thus, to resolve this issue, we integrated the T promoter into our VISA amplification system (15) 
T-VISA nanoparticles are specifically activated in breast tumors
To further investigate whether the specificity and activity of T-VISA expression is still retained in vivo, we treated the 4T1 tumor-bearing mice with the plasmid DNA/nanoparticle complexes carrying either CMV-Luc or T-VISA-Luc via the tail vein. The T-VISA-Luc exhibited significant luciferase activity primarily at the tumor region ( Fig. 2A) . In contrast, the majority of the luciferase activity of CMV-Luc was found in the lungs and heart with weak signals in the tumor area. To more precisely evaluate the source of signal, we sacrificed the mice immediately after in vivo imaging and harvested the corresponding organs for ex vivo imaging (Fig. 2B ). In addition, we also measured the luciferase activity of the dissected organs by a luminometer (Fig. 2C) . The in vivo results demonstrated that T-VISA is specific in breast tumor mouse model. 
To test whether the T-VISA vector can target a therapeutic gene to breast cancer cells, we constructed CMV-BikDD and T-VISA-BikDD plasmids (Fig. 3A) . The (Fig. 4D) . Quatitative analysis of apoptosis suggested that the levels of apoptosis CMV-BikDD treatment group were relatively high in normal tissues but the relatively low in both T-VISA-BikDD and control groups. by T-VISA or CMV demonstrated a strong reduction in tumor growth (P = 0.0039 and P = 0.0092, respectively), but tumor inhibition by T-VISA-BikDD was more substantial than CMV-BikDD (Fig. 5A ). In addition, T-VISA-BikDD significantly prolonged the survival time of mice more effectively than CMV-BikDD (P = 0.034), although the survival time of mice in treatment groups had all been extended compared to control group (P < 0.0001 in both treatment groups) (Fig. 5B ). These 
T-VISA-
6C, D). These results indicate that administration of T-VISA-BikDD is much safer
than CMV-BikDD. We did not, however, observe any increase in the BUN level at any assayed time points in mice treated with control, CMV-BikDD or T-VISA-BikDD (Fig. 6E) . In addition, T-VISA-BikDD-liposome complexes showed 100% event-free survival compared with 80% or 60% in CMV-BikDD treated mice at a dose of 50 or 100 μg DNA (Fig. 6A and B) . To further investigate apoptosis in vivo, tissues from mice per group were sectioned and detected by TUNEL assay (Fig. 6F) . Analyzes of apoptosis showed that CMV-BikDD treatment induced a remarkable amount of apoptosis in both lung and liver tissues compared with control and T-VISA-BikDD groups. The percentage of apoptosis cells in CMV-BikDD treatment group was significantly higher than control or T-VISA-BikDD groups (P < 0.001). Taken together, our findings suggest that T-VISA-BikDD-liposome-mediated systemic gene therapy provides an effective therapeutic approach in multiple animal models with relatively safe profile compared with the commonly used CMV promoter-driven vector, thereby acting as a potent anticancer agent for breast cancer.
Discussion
The human telomerase reverse transcriptase (T) is highly expressed in a majority of cancer types but not in normal cells, which allows it to be used as a tumor biomarker (15, 17, 18) . Previously, we identified and validated the specificity of the T promoter in ovarian cancer and showed that its activity was enhanced by the VISA amplification system (15) . In this study, our results further demonstrated that the T promoter is specifically activated in breast cancer cells but had much weaker activity than the CMV promoter. Using the VISA system that was initially developed for pancreatic cancer (13), we have since then demonstrated that this system is highly 
active in ovarian (15) , lung (16) and liver (30) cancers. With the goal of further developing a robust and breast tumor-specific vector, we incorporated the T promoter into our VISA system and constructed T-VISA expression carrier. Our engineered T-VISA is a composite that contains three basic elements: the T promoter, the TSTA system, and the WPRE sequence. T-VISA specifically controls expression of BikDD in breast cancer, involving five steps: 1) The T promoter drives the GAL4-VP2 (two copies of VP16) fusion protein specifically in breast cancer cells, not in normal cells;
2) GAL4-VP2 unlocks target gene BikDD mRNA transcripts; 3) the BikDD mRNA transcripts involves the WPRE element, which can stabilize RNA transcripts; 4) the BikDD mRNA transcripts then improve and extend duration of BikDD protein expression, and 5) BikDD binds to Bcl-2, and releases Bax and Bid, leading to apoptosis of breast cancer cells. For normal cells, the activity of T promoter is much lower, resulting in very limited gene expression and, thereafter, cell survival.
Thus, the activity of T-VISA is higher than or comparable with CMV promoter in breast cancer cells but low in normal cells. In addition, the duration of transgene expression induced by T-VISA was also prolonged as well, which can be explained by the presence of WPRE in the VISA system (13, 14) . assessed and the results were consistent with the above study (Fig. 6) . Thus, our T-VISA-BikDD system has the following advantages over the CMV-BikDD system: 1) has prolonging-expression of therapeutic gene BikDD, which can improve the treatment efficacy and decrease the dosage and frequency of treatment; and 2) exhibits cancer-targeted expression of BikDD, which can reduce the in vivo toxicity.
In conclusion, our present data, derived from both in vitro and in vivo studies suggest that VISA-BikDD nanoparticles not only retain high specificity but also strong activity in breast cancer. With VISA-BikDD exerting robust tumor inhibition effects, target specificity, and less side effects, there would be no hesitation to test it in future clinical trial with the hope that it might become a novel therapeutic option for breast cancer patients.
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